--- title: "MED.B.030 Haematology — Part-MED · Avioverse" description: "Applicants for a class 1 medical certificate shall be subjected to an haemoglobin test at each aero-medical examination." url: "https://avioverse.aero/regulations/easa/aircrew/part-med/subpart-b/med-b-030" --- # MED.B.030 Haematology ANNEX IV (Part-MED) · Regulation (EU) No 1178/2011 · EAR revision 25 Nov 2025 IR Implementing rule ## MED.B.030 Haematology (a) Applicants for a class 1 medical certificate shall be subjected to an haemoglobin test at each [aero-medical examination](https://avioverse.aero/glossary/easa/aero-medical-examination). (b) Applicants with a haematological condition may be assessed as fit subject to satisfactory aero-medical evaluation. (c) Applicants for a class 1 medical certificate with any of the following haematological conditions shall be referred to the medical assessor of the [licensing authority](https://avioverse.aero/glossary/easa/licensing-authority): (1) abnormal haemoglobin, including, but not limited to anaemia, erythrocytosis or haemoglobinopathy; (2) [significant](https://avioverse.aero/glossary/easa/significant) lymphatic enlargement; (3) enlargement of the spleen; (4) coagulation, haemorrhagic or thrombotic disorder; (5) leukaemia. (d) The fitness of applicants for a class 2 medical certificate with any of the haematological conditions specified in points (4) and (5) of point (c) shall be assessed in consultation with the medical assessor of the licensing authority. IR · MED.B.030 — Regulation (EU) No 1178/2011 · Regulation (EU) 2019/27 · Aircrew Easy Access Rules · EAR revision 25 Nov 2025 AMC Acceptable means of compliance ## AMC1 MED.B.030 Haematology (a) Abnormal haemoglobin Applicants with abnormal haemoglobin should be investigated. (b) Anaemia (1) Applicants with anaemia demonstrated by a reduced haemoglobin level require [investigation](https://avioverse.aero/glossary/easa/investigation). Applicants with an haematocrit of less than 32 % should be assessed as unfit. A fit assessment may be considered in cases where the primary cause, such as iron or B12 deficiency, has been treated and the haemoglobin or haematocrit has stabilised at a satisfactory level. (2) Applicants with anaemia which is unamenable to treatment should be assessed as unfit. (c) Erythrocytosis Applicants with erythrocytosis should be assessed as unfit. A fit assessment with an OML may be considered if investigation establishes that the condition is stable and no associated pathology is demonstrated. (d) Haemoglobinopathy (1) Applicants with a haemoglobinopathy should be assessed as unfit. A fit assessment may be considered where minor thalassaemia or other haemoglobinopathy is diagnosed without a history of crises and where full functional capability is demonstrated. The haemoglobin level should be satisfactory. (2) Applicants with sickle cell disease (homozygote) should be assessed as unfit. (e) Coagulation disorders (1) Applicants with a coagulation disorder should be assessed as unfit. A fit assessment may be considered if there is no history of [significant](https://avioverse.aero/glossary/easa/significant) bleeding episodes. (2) Applicants with thrombocytopenia with a platelet count less than 75x109/L should be assessed as unfit. A fit assessment may be considered once the platelet count is above 75x109/L and stable. (f) Haemorrhagic disorders Applicants with a haemorrhagic disorder require investigation. A fit assessment with an OML may be considered if there is no history of significant bleeding. (g) Thromboembolic disorders (1) Applicants with a thrombotic disorder require investigation. A fit assessment may be considered when the [applicant](https://avioverse.aero/glossary/easa/applicant) is asymptomatic and there is only minimal risk of secondary complication or recurrence. (2) If anticoagulation is used as treatment, refer to AMC1 MED.B.010(g). (3) Applicants with arterial embolus should be assessed as unfit. A fit assessment may be considered once recovery is complete, the applicant is asymptomatic, and there is only minimal risk of secondary complication or recurrence. (h) Disorders of the lymphatic system Applicants with significant localised and generalised enlargement of the lymphatic glands or haematological disease should be assessed as unfit and require investigation. A fit assessment may be considered in cases of an acute infectious process which is fully recovered or Hodgkin’s lymphoma or other lymphoid malignancy which has been treated and is in full remission. (i) Leukaemia (1) Applicants with acute leukaemia should be assessed as unfit. Once in established remission, applicants may be assessed as fit. (2) Applicants with chronic leukaemia should be assessed as unfit. After a period of demonstrated stability a fit assessment may be considered. (3) Applicants with a history of leukaemia should have no history of central nervous system involvement and no continuing side-effects from treatment of flight safety importance. Haemoglobin and platelet levels should be satisfactory. Regular follow-up is required. (j) Splenomegaly Applicants with splenomegaly should be assessed as unfit and require investigation. A fit assessment may be considered when the enlargement is minimal, stable and no associated pathology is demonstrated, or if the enlargement is minimal and associated with another acceptable condition. AMC · AMC1 MED.B.030 — Regulation (EU) No 1178/2011 · ED Decision 2019/002/R · Aircrew Easy Access Rules · EAR revision 25 Nov 2025 AMC Acceptable means of compliance ## AMC2 MED.B.030 Haematology (a) Abnormal haemoglobin Haemoglobin should be tested when clinically indicated. (b) Anaemia Applicants with anaemia demonstrated by a reduced haemoglobin level or low haematocrit may be assessed as fit once the primary cause has been treated and the haemoglobin or haematocrit has stabilised at a satisfactory level. (c) Erythrocytosis Applicants with erythrocytosis may be assessed as fit if the condition is stable and no associated pathology is demonstrated. (d) Haemoglobinopathy Applicants with a haemoglobinopathy may be assessed as fit if minor thalassaemia or other haemoglobinopathy is diagnosed without a history of crises and where full functional capability is demonstrated. (e) Coagulation and haemorrhagic disorders Applicants with a coagulation or haemorrhagic disorder may be assessed as fit if there is no likelihood of [significant](https://avioverse.aero/glossary/easa/significant) bleeding. (f) Thromboembolic disorders Applicants with a thrombotic disorder may be assessed as fit if there is minimal likelihood of significant clotting episodes. If anticoagulation is used as treatment, refer to AMC2 MED.B.010(g). (g) Disorders of the lymphatic system Applicants with significant enlargement of the lymphatic glands or haematological disease may be assessed as fit if the condition is unlikely to interfere with the safe exercise of the privileges of the applicable licence(s). Applicants may be assessed as fit in cases of acute infectious process which is fully recovered or Hodgkin's lymphoma or other lymphoid malignancy which has been treated and is in full remission. (h) Leukaemia (1) Applicants with acute leukaemia may be assessed as fit once in established remission. (2) Applicants with chronic leukaemia may be assessed as fit after a period of demonstrated stability. (3) In cases (h)(1) and (h)(2), there should be no history of central nervous system involvement and no continuing side effects from treatment of flight safety importance. Haemoglobin and platelet levels should be satisfactory. Regular follow-up is required. (i) Splenomegaly Applicants with splenomegaly may be assessed as fit if the enlargement is minimal, stable and no associated pathology is demonstrated, or if the enlargement is minimal and associated with another acceptable condition. AMC · AMC2 MED.B.030 — Regulation (EU) No 1178/2011 · ED Decision 2019/002/R · Aircrew Easy Access Rules · EAR revision 25 Nov 2025 [All rules in SUBPART B – REQUIREMENTS FOR PILOT MEDICAL CERTIFICATES](https://avioverse.aero/regulations/easa/aircrew/part-med/subpart-b) Consolidated from the EASA Easy Access Rules (revision 25 Nov 2025, extracted 13 Oct 2026) for convenience. Not the official publication — verify against the Official Journal of the European Union and the EASA publications before operational use.